Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMGN

ImmunoGen (IMGN) Stock Price, News & Analysis

ImmunoGen logo

About ImmunoGen Stock (NASDAQ:IMGN)

Advanced Chart

Key Stats

Today's Range
$31.23
$31.23
50-Day Range
$31.23
$31.23
52-Week Range
$3.61
$31.25
Volume
40 shs
Average Volume
8.78 million shs
Market Capitalization
$8.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

ImmunoGen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

IMGN MarketRank™: 

ImmunoGen scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ImmunoGen.

  • Earnings Growth

    Earnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for IMGN.
  • Dividend Yield

    ImmunoGen does not currently pay a dividend.

  • Dividend Growth

    ImmunoGen does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for IMGN.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for ImmunoGen this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmunoGen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.07% of the stock of ImmunoGen is held by insiders.

  • Percentage Held by Institutions

    90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ImmunoGen's insider trading history.
Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Artisan International Small-Mid Instl
Artisan International Small-Mid Advisor
See More Headlines

IMGN Stock Analysis - Frequently Asked Questions

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Monday, July, 31st. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The business's revenue for the quarter was up 485.9% on a year-over-year basis.
Read the conference call transcript
.

ImmunoGen subsidiaries include Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), General Electric (GE), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
7/31/2023
Today
4/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMGN
Employees
277
Year Founded
1981

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
390.38
P/E Growth
N/A
Net Income
$-222,930,000.00
Pretax Margin
-25.24%

Debt

Sales & Book Value

Annual Sales
$287.61 million
Price / Cash Flow
N/A
Book Value
$0.71 per share
Price / Book
43.99

Miscellaneous

Free Float
252,764,000
Market Cap
$8.32 billion
Optionable
Optionable
Beta
1.18

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IMGN) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners